Literature DB >> 2068428

A comparison of two simple hazard ratio estimators based on the logrank test.

G Berry1, R M Kitchin, P A Mock.   

Abstract

Two hazard ratio estimators based on the logrank test are investigated using a simulation study. The Pike estimator (ratio of relative death rates) was shown to be consistently less biased than the Peto (1-step) estimator. The latter has recently been advocated as the method of choice for point and interval estimation. Both estimators exhibited bias with increasing hazard ratios, although the bias was minimal for effects less than 3. The confidence intervals also did not achieve the nominal coverage with increasing hazard ratios, but again the Pike estimator was superior. The coverage could be improved by recalculation of the variance incorporating the point estimate. For a hazard ratio of less than 3 we recommend the use of the Pike estimator, otherwise it is necessary to use a more complex method of estimation.

Entities:  

Mesh:

Year:  1991        PMID: 2068428     DOI: 10.1002/sim.4780100510

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  14 in total

1.  Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV.

Authors:  S Stolnicu; I Barsan; L Hoang; P Patel; C Terinte; A Pesci; S Aviel-Ronen; T Kiyokawa; I Alvarado-Cabrero; E Oliva; K J Park; N R Abu-Rustum; M C Pike; R A Soslow
Journal:  Gynecol Oncol       Date:  2018-05-30       Impact factor: 5.482

2.  Conditional survival of high-grade glioma in Los Angeles County during the year 1990-2000.

Authors:  Denice D Tsao-Wei; Jia Hu; Susan G Groshen; Marc C Chamberlain
Journal:  J Neurooncol       Date:  2012-08-09       Impact factor: 4.130

3.  Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

Authors:  Marc C Chamberlain; Sandra K Johnston
Journal:  J Neurooncol       Date:  2009-07-11       Impact factor: 4.130

4.  Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

Authors:  Marc C Chamberlain; Sandra Johnston
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

5.  Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Authors:  Robert J Motzer; Naomi B Haas; Frede Donskov; Marine Gross-Goupil; Sergei Varlamov; Evgeny Kopyltsov; Jae Lyun Lee; Bohuslav Melichar; Brian I Rini; Toni K Choueiri; Milada Zemanova; Lori A Wood; M Neil Reaume; Arnulf Stenzl; Simon Chowdhury; Ho Yeong Lim; Ray McDermott; Agnieszka Michael; Weichao Bao; Marlene J Carrasco-Alfonso; Paola Aimone; Maurizio Voi; Christian Doehn; Paul Russo; Cora N Sternberg
Journal:  J Clin Oncol       Date:  2017-09-13       Impact factor: 44.544

6.  Gender-related survival differences associated with polymorphic variants of estrogen receptor-β (ERβ) in patients with metastatic colon cancer.

Authors:  O A Press; W Zhang; M A Gordon; D Yang; C A Haiman; M Azuma; S Iqbal; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2010-06-15       Impact factor: 3.550

7.  Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

Authors:  Anirban P Mitra; Vincenzo Pagliarulo; Dongyun Yang; Frederic M Waldman; Ram H Datar; Donald G Skinner; Susan Groshen; Richard J Cote
Journal:  J Clin Oncol       Date:  2009-07-20       Impact factor: 44.544

8.  Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program.

Authors:  Anirban P Mitra; Jose E Castelao; Debra Hawes; Denice D Tsao-Wei; Xuejuan Jiang; Shan-Rong Shi; Ram H Datar; Eila C Skinner; John P Stein; Susan Groshen; Mimi C Yu; Ronald K Ross; Donald G Skinner; Victoria K Cortessis; Richard J Cote
Journal:  Cancer       Date:  2013-01-14       Impact factor: 6.860

9.  On confidence intervals for the hazard ratio in randomized clinical trials.

Authors:  Dan-Yu Lin; Luyan Dai; Gang Cheng; Martin Oliver Sailer
Journal:  Biometrics       Date:  2016-04-28       Impact factor: 2.571

10.  CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.

Authors:  Marc C Chamberlain; Michael J Glantz
Journal:  J Neurooncol       Date:  2008-05-15       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.